Addendum
Lazertinib (NSCLC, first line, combination with amivantamab) - Addendum to Project A25-11
Report documents
-
Addendum
Lazertinib (NSCLC, first line, combination with amivantamab) - Addendum to Project A25-11
Dossier assessment
Indication:
Adult patients with advanced non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations; first-line treatment
Result of dossier assessment:
- Patients < 65 years: hint of a minor added benefit
- Patients ≥ 65 years: hint of a lesser benefit
Additional information
Federal Joint Committee (G-BA)
17.07.2025 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A25-77
- Commission
- Commission awarded on 12.06.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A25-78
Connected Projects
-
Dossier assessment
Lazertinib (NSCLC, first line, in combination with amivantamab) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Amivantamab (NSCLC, first line, combination with lazertinib) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed